P/E ratio for Merck (MRK)
P/E ratio as of May 2024 (TTM): 71.4
According to Merck's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 71.3956. At the end of 2022 the company had a P/E ratio of 19.4.
P/E ratio history for Merck from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 19.4 | 30.52% |
| 2021 | 14.8 | -46.83% |
| 2020 | 27.9 | 23.54% |
| 2019 | 22.6 | -27.17% |
| 2018 | 31.0 | -45.92% |
| 2017 | 57.4 | 110.42% |
| 2016 | 27.3 | -14.4% |
| 2015 | 31.8 | 144.67% |
| 2014 | 13.0 | -59.55% |
| 2013 | 32.2 | 79.31% |
| 2012 | 17.9 | 1.85% |
| 2011 | 17.6 | -85.61% |
| 2010 | 122 | 1892.66% |
| 2009 | 6.14 | -23.13% |
| 2008 | 7.99 | -114.99% |
| 2007 | -53.3 | -361.43% |
| 2006 | 20.4 | 41.77% |
| 2005 | 14.4 | 23.83% |
| 2004 | 11.6 | -22% |
| 2003 | 14.9 | -12.32% |
| 2002 | 17.0 | -3.72% |
| 2001 | 17.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -85.09% | 🇺🇸 USA |
 Novartis NVS | 27.3 | -61.76% | 🇨🇭 Switzerland |
 Pfizer PFE | 15.1 | -78.91% | 🇺🇸 USA |
 Abbott Laboratories ABT | 35.2 | -50.64% | 🇺🇸 USA |
 Eli Lilly LLY | 140 | 96.06% | 🇺🇸 USA |
 Amgen AMGN | 21.9 | -69.30% | 🇺🇸 USA |
 Sanofi SNY | 15.5 | -78.30% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 11.3 | -84.14% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 12.9 | -81.97% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -8.13 | -111.38% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.